Suppr超能文献

原发性甲状腺淋巴瘤的临床病理特征及 A20 突变。

Clinicopathologic Characteristics and A20 Mutation in Primary Thyroid Lymphoma.

机构信息

Department of Hematology, Nippon Medical School.

Department of Microbiology and Immunology, Nippon Medical School.

出版信息

J Nippon Med Sch. 2022 Jun 28;89(3):301-308. doi: 10.1272/jnms.JNMS.2022_89-305. Epub 2021 Nov 26.

Abstract

BACKGROUND

Primary thyroid lymphoma (PTL) is a rare disease frequently arising against a background of autoimmune thyroiditis. It has recently been reported that the inactivation of the NF-κB negative regulator A20 by deletion and/or mutation could be involved in the pathogenesis of subsets of B-cell lymphomas. This study investigated the clinicopathologic characteristics and A20 mutation in patients with PTL.

METHODS

We analyzed the characteristics of 45 PTL patients (14 men and 31 women), with a median age of 71 (range, 35-90) years. A20 mutations were analyzed in DNA extracted from 20 samples consisting of 19 tumor tissue samples and 1 sample from Hashimoto's thyroiditis.

RESULTS

Thirty-five patients (82%) had a history of Hashimoto's thyroiditis, and 29 (64%) had diffuse large B-cell lymphoma (DLBCL) and presented with larger tumors including bulky mass, elevated soluble interleukin-2 receptor levels, and a longer history of Hashimoto's thyroiditis than that of patients with mucosa-associated lymphoid tissue (MALT) lymphoma (n=16). A20 mutations were identified in 3 of 19 PTL patients (16%), in 2 of the 10 (20%) with DLBCL and in 1 of the 9 (11%) with MALT lymphoma. Interestingly, all patients with A20 mutations had Hashimoto's thyroiditis. Furthermore, they had a common missense variant in exon 3 (rs2230926 380T>G; F127C), which reduces the ability of A20 to inhibit NF-κB signaling.

CONCLUSION

Our study suggests that the histological features of PTL affect clinical outcomes and that A20 mutations are related to PTL pathogenesis in some patients with Hashimoto's thyroiditis.

摘要

背景

原发性甲状腺淋巴瘤(PTL)是一种罕见疾病,常发生在自身免疫性甲状腺炎的背景下。最近有报道称,NF-κB 负调节因子 A20 的缺失和/或突变失活可能与部分 B 细胞淋巴瘤的发病机制有关。本研究调查了 PTL 患者的临床病理特征和 A20 突变情况。

方法

我们分析了 45 例 PTL 患者(14 例男性,31 例女性)的特征,中位年龄为 71 岁(范围,35-90 岁)。从 19 例肿瘤组织样本和 1 例桥本甲状腺炎样本中提取 DNA,分析 A20 突变。

结果

35 例(82%)患者有桥本甲状腺炎病史,29 例(64%)患者为弥漫性大 B 细胞淋巴瘤(DLBCL),且肿瘤较大,包括肿块较大、可溶性白细胞介素-2 受体水平升高、桥本甲状腺炎病史较长,而黏膜相关淋巴组织(MALT)淋巴瘤(n=16)患者的肿瘤较小。在 19 例 PTL 患者中发现 A20 突变 3 例(16%),在 10 例 DLBCL 中发现 2 例(20%),在 9 例 MALT 淋巴瘤中发现 1 例(11%)。有趣的是,所有 A20 突变患者均有桥本甲状腺炎。此外,他们在exon 3 都有一个常见的错义变异(rs2230926 380T>G;F127C),这降低了 A20 抑制 NF-κB 信号的能力。

结论

本研究表明,PTL 的组织学特征影响临床结局,A20 突变与某些桥本甲状腺炎患者的 PTL 发病机制有关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验